Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

2026 data Public-data reference. official source

Eczema

Open-data reference.

30 US clinical trials · 13 currently recruiting

Active & Recent Trials

RECRUITING 900 participants

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

University of California, San Diego

NCT05938478

RECRUITING 530 participants

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

National Human Genome Research Institute (NHGRI)

NCT00605878

RECRUITING NA 250 participants

Flourish: Exploring the Early Infant Gut Microbiome

Seeding

NCT07333482

RECRUITING Phase 2 220 participants

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Inmagene

NCT07037901

RECRUITING 200 participants

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

University of Pittsburgh

NCT00177268

RECRUITING Phase 2 200 participants

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Corvus Pharmaceuticals

NCT07441395

RECRUITING Phase 3 150 participants

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Pfizer

NCT06807268

RECRUITING Phase 2 130 participants

Effects of Treatments on Atopic Dermatitis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT01631617

RECRUITING Phase 1 125 participants

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Arcutis Biotherapeutics

NCT07453602

RECRUITING Phase 2 120 participants

Cardamom and Topical Roseomonas in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06096857

RECRUITING Phase 2 100 participants

A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis)

Turn Therapeutics

NCT07355075

RECRUITING Phase 2 96 participants

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Aclaris Therapeutics

NCT07011706

RECRUITING 90 participants

Sodium in the Skin and Atopic Dermatitis

University of California, San Francis

NCT06998446

ACTIVE NOT RECRUITING 505 participants

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

Northwestern University

NCT01782703

ACTIVE NOT RECRUITING Phase 2 398 participants

Seal, Stopping Eczema and Allergy Study

Kari Nadeau, MD, PhD

NCT03742414

ACTIVE NOT RECRUITING Phase 3 367 participants

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company

NCT05559359

ACTIVE NOT RECRUITING NA 100 participants

Infant Restore: Efficacy of Microbiome Analysis and Education

Seeding

NCT06424691

COMPLETED Phase 3 599 participants

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

Stiefel, a GSK Company

NCT00817063

COMPLETED NA 300 participants

Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis

University of Southern California

NCT03981926

COMPLETED Phase 2 180 participants

Preliminary Study of Safety and Efficacy of Nanocrystalline Silver Cream in Atopic Dermatitis (Eczema)

Nucryst Pharmaceuticals

NCT00076375

COMPLETED Phase 2 87 participants

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

Janssen Research & Development

NCT04021862

COMPLETED NA 63 participants

Joovvin' for Your Skin Health Study

ProofPilot

NCT04471896

COMPLETED 60 participants

Oral Bacteria and Allergic Disease in Children

National Institute of Environmental Health Sciences (NIEHS)

NCT00438646

COMPLETED 59 participants

Sleep, Circadian Rhythm & Skin Health

University Hospitals Cleveland Medical Center

NCT02457000

COMPLETED Phase 4 30 participants

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Ann & Robert H Lurie Children's Hospital of Chicago

NCT04023084

COMPLETED Phase 4 30 participants

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

Frankel, Amylynne, M.D.

NCT01202149

COMPLETED 30 participants

Bone Health in Patients With Atopic Dermatitis

Mayo Clinic

NCT03800004

COMPLETED Phase 1 28 participants

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

AOBiome

NCT03775434

COMPLETED Phase 4 24 participants

Steroid-reducing Effects of Crisaborole

Johns Hopkins University

NCT03832010

COMPLETED NA 9 participants

Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy

Rockefeller University

NCT01149759

Phase Distribution

PhaseTrial count
Early Phase 1 2
Phase 2 9
Phase 3 3
Phase 4 3

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Eczema Trial Landscape

ClinicalTrials.gov lists 30 US studies indexed under Eczema, and 13 of those are currently open to recruitment — roughly 43% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Eczema shows 6 late-stage studies (Phase 3 and Phase 4 combined) alongside 11 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Eczema is led by Seeding with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 30 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Eczema?

PlainTrial tracks 30 US clinical trials for Eczema, of which 13 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Eczema?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →